Analysts’ Recent Ratings Changes for Hinge Health (HNGE)

A number of firms have modified their ratings and price targets on shares of Hinge Health (NYSE: HNGE) recently:

• 5/10/2026 – Hinge Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/6/2026 – Hinge Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/6/2026 – Hinge Health was given a new $79.00 price target by Truist Financial Corporation.
• 5/6/2026 – Hinge Health had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $70.00 price target on the stock.
• 5/6/2026 – Hinge Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $95.00 price target on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $55.00 to $65.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $53.00 to $63.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Hinge Health had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/6/2026 – Hinge Health had its price target raised by Barclays PLC from $52.00 to $62.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Stifel Nicolaus from $59.00 to $67.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Citizens Jmp from $65.00 to $80.00. They now have a “market outperform” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Wells Fargo & Company from $68.00 to $80.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Needham & Company LLC from $59.00 to $63.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Hinge Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/8/2026 – Hinge Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $45.00 price target on the stock.

Insider Activity at Hinge Health

In other Hinge Health news, CFO James Budge sold 11,006 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $42.26, for a total transaction of $465,113.56. Following the transaction, the chief financial officer directly owned 401,427 shares of the company’s stock, valued at approximately $16,964,305.02. The trade was a 2.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Antonio Perez sold 166,665 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $40.26, for a total transaction of $6,709,932.90. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 648,576 shares of company stock valued at $30,122,850 in the last 90 days. 18.92% of the stock is owned by company insiders.

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.